Researchers from Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center presented new data demonstrating the efficacy of Clorox Healthcare Fuzion Cleaner Disinfectant at IDWeek 2017. The study showed that Clorox Healthcare Fuzion Cleaner Disinfectant was as effective for killing Clostridium difficile (C. difficile) spores, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Escherichia coli as a standard bleach product, but was less damaging to surfaces and left less residue on surfaces.

Both bleach formulations reduced each of the pathogens by ≥6.0 log(10)CFU with a two-minute contact time. An assessment of real-world materials compatibility of the products by repeated spray applications on a hospital mattress, formica bedside table, and textiles, found that Fuzion caused minimal to no adverse effects with up to 60 applications. Personnel using the products also reported that Fuzion left much less residue after use and was more tolerable than the standard bleach product.

The research team led by Curtis J. Donskey, MD, Professor of Medicine at Case Western Reserve University and Infectious Disease Physician at the Louis Stokes Cleveland VA Medical Center, presented the findings as a poster abstract on October 5, 2017 at the IDWeek conference in San Diego.

“Contaminated surfaces are a potential source for dissemination of pathogens in the health care environment,” said Donskey. “Our results confirm the product’s efficacy against clinically relevant health care pathogens and suggest that Fuzion may provide an alternative sporicidal disinfectant for facilities concerned about surface compatibility.”

Fuzion is the next generation of bleach and the first product of its kind to combine trusted bleach efficacy against tough-to-kill pathogens with the aesthetics required for broad use throughout health care facilities.